Suppr超能文献

外用环孢素A长期治疗1型自身免疫性多腺体综合征的角膜炎

Long term keratits treatment with topical cyclosporin a in autoimmune polyglandular syndrome type 1.

作者信息

AlAbbasi Omar, Magliyah Moustafa S, Ahad Muhammad

机构信息

Cornea and Anterior Segment Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

Ophthalmology Department, Ohud Hospital, Madinah, Saudi Arabia.

出版信息

Am J Ophthalmol Case Rep. 2021 Jan 6;21:101009. doi: 10.1016/j.ajoc.2020.101009. eCollection 2021 Mar.

Abstract

PURPOSE

To report long term results of two cases treated with topical cyclosporin A 1% for keratitis associated with autoimmune polyglandular syndrome (APS1).

OBSERVATIONS

A 25-year-old male and a 17-year-old female were referred from endocrinology as APS1-related autoimmune keratitis. Extended-duration treatment with topical cyclosporin A (CsA) 1% was used for 24 and 18 months, respectively. The first patient had improved best-corrected visual acuity (BCVA) from 20/200 and 20/300 in right and left eye to 20/60 in both eyes with markedly improved corneal opacification, while the second patient had improved BCVA from 20/400 and 20/300 in right and left eye to 20/160 in both eyes with persistent central stromal scarring in the right eye and discrete areas of stromal scarring in the left eye.

CONCLUSIONS AND IMPORTANCE

Long-term topical CsA 1% offers a valuable option for treatment of APS1-related autoimmune keratitis.

摘要

目的

报告两例使用1%环孢素A局部治疗与自身免疫性多腺体综合征(APS1)相关的角膜炎的长期结果。

观察结果

一名25岁男性和一名17岁女性因APS1相关的自身免疫性角膜炎被内分泌科转诊。分别使用1%环孢素A(CsA)进行了24个月和18个月的长期局部治疗。首例患者右眼和左眼的最佳矫正视力(BCVA)从20/200和20/300提高到双眼20/60,角膜混浊明显改善;而第二例患者右眼和左眼的BCVA从20/400和20/300提高到双眼20/160,右眼有持续性中央基质瘢痕,左眼有散在的基质瘢痕区域。

结论与意义

长期局部使用1% CsA为治疗APS1相关的自身免疫性角膜炎提供了一种有价值的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25f4/7809181/95576b00cc26/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验